4G Clinical Funding, Investors & Competitors

4G Clinical has raised $252M across 4 funding rounds, most recently a $230M undisclosed-stage round in June 2021.

Last 4G Clinical funding round

$230M

Undisclosed stage · Jun 2021

Cumulative funding 4G Clinical raised

$252M

across 4 funding rounds

Key investors in 4G Clinical

  • Schooner Capital
  • Goldman Sachs Asset Management

4G Clinical Overview

About 4G Clinical

4G Clinical is a software provider for clinical trial randomization and trial supply management headquartered in Wellesley, Massachusetts. Founded in 2015, its Prancer RTSM platform employs natural language processing for forecasting and supply chain optimization in pharmaceutical trials. The company supports global CROs and biotechs with advisory services, reducing timelines by integrating with EDC systems. 4G Clinical manages supplies for Phase I-IV studies across 50+ countries.


Founded

2015

HQ

United StatesUnited States

Status

Privately held

Customer focus

B2B

Revenue model

Subscription

4G Clinical Funding History

4G Clinical has raised a total of $252M across 4 funding rounds.

4G Clinical's first fundraising round was a $3M Series A in January 2016. The most recent completed round was a $230M undisclosed-stage round in June 2021.

4G Clinical funding rounds

4G Clinical funding rounds
DateStageInvestorsRaisedDeal Summary
Jun 2021Undisclosed stageGoldman Sachs Asset Management (lead)$230M4G Clinical is a Wellesley, Massachusetts-based company founded in 2015 by David Kelleher and Ed Tourtellotte, specializing in randomization and trial supply management (RTSM) software for clinical trials. The company leverages natural language processing (NLP) in its cloud-based Prancer RTSM platform to accelerate trial setup, enabling first patient in (FPI) up to 50% faster than competitors, and 4C Supply for clinical supply optimization to minimize stock-outs and drug waste. It supports trials for over 100 biotech and pharma clients worldwide, with offices in Europe and Asia, and had grown to 230 employees by mid-2021. On June 29, 2021, 4G Clinical announced a growth equity investment exceeding $230 million led by Goldman Sachs Asset Management, with First Analysis exiting its position from a 2019 investment as part of the transaction. The funds are designated for global expansion, meeting rising product demand, enhancing technology innovation, go-to-market strategies, and R&D to address clinical trial complexities in the expanding eClinical solutions market. CEO David Kelleher described the investment as transformational, positioning the company as a leader in RTSM amid rapid market growth driven by tech-first solutions. The round attracted interest due to 4G Clinical's modern technology stack using Python, Angular, PostgreSQL, and Django on AWS with Google Cloud redundancy, differentiating it from incumbents like Oracle and Medidata Solutions. Goldman Sachs Managing Directors Jason Kreuziger, Antoine Munfa, and Mike Reilly highlighted the company's best-in-class product, experienced team, and favorable tailwinds in eClinical software.
Dec 2019Series A-$15M4G Clinical raised $14.6 million in a Series C funding round filed on January 14, 2020, led by investors including First Analysis and Schooner Capital. The company provides cloud-based randomization and trial supply management (RTSM) software using natural language processing to accelerate clinical trials for life sciences firms. Headquartered in Wellesley, Massachusetts, 4G Clinical serves biotech and pharma clients with its Prancer platform to handle complex trial designs.
Oct 2016Series ASchooner Capital (lead)$5M4G Clinical raised $5 million in Series A1 financing on October 19, 2016, led by Schooner Capital, bringing its total Series A funding to $7.5 million including a prior $2.5 million tranche announced in January 2016. The company develops Prancer, a fourth-generation Randomization and Trial Supply Management (RTSM) platform leveraging modern technology and natural language processing to simplify clinical trials. Funds supported operations, product development, marketing, team expansion from a handful to 24 staff, and global client service.
Jan 2016Series ASchooner Capital (lead)$3M4G Clinical, a clinical trials software company, secured a $2.5 million Series A funding round on January 19, 2016, led by Schooner Capital. The funds supported business and technology development, talent recruitment, and brand promotion at industry conferences. This initial tranche was followed by an additional $5 million in Series A1 financing in October 2016, bringing the total Series A to $7.5 million, all led by Schooner Capital. 4G Clinical develops Prancer, a fourth-generation Randomization and Trial Supply Management (RTSM) system using a modern tech stack and natural language processing for Phase 2 and 3 clinical trials. The company was founded by industry veterans Ed Tourtellotte and David Kelleher to address unmet needs in drug development.

Who has invested in 4G Clinical?

2 investors have backed 4G Clinical across its funding rounds, including Schooner Capital and Goldman Sachs Asset Management.

Lead investors include Goldman Sachs Asset Management and Schooner Capital.


4G Clinical Investors

Investors in 4G Clinical by funding rounds participated
InvestorHQRoundsRoleFirst check

This data is available for Pro users. Sign up to see all 2 4G Clinical investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

4G Clinical Competitors

4G Clinical competitors include listed companies like IQVIA, IDEXX Laboratories, GE HealthCare and ICON plc, and private ones like Benchling and Dental Monitoring.

Public and private companies comparable to 4G Clinical
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
BenchlingUnited StatesSan Francisco, CAPrivate$210M-$6.1B29.0x
IQVIAUnited StatesUnited StatesPublicly listed$16B$3.4B$44B3.4x
IDEXX LaboratoriesUnited StatesUnited StatesPublicly listed$4.3B$1.5B$40B8.9x
GE HealthCareUnited StatesUnited StatesPublicly listed$21B$3.7B$29B1.8x
ICON plcUnited StatesUnited StatesPublicly listed$8.3B$816M$13B1.9x
Dental MonitoringFranceParisPrivate$91M-$1B-

4G Clinical Public Comps

4G Clinical is still privately-owned, but its public comps include Merck KGaA, IQVIA, Veeva, IDEXX Laboratories, Roper Technologies, Illumina, GE HealthCare, Sartorius, ICON plc and Pro Medicus.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Merck KGaA$24B$5.3B3.1x3.1x14.3x10.7x
IQVIA$16B$3.4B3.6x3.4x17.2x14.8x
Veeva$3.2B$965M11.1x10.2x36.9x22.4x
IDEXX Laboratories$4.3B$1.5B9.5x8.9x27.1x24.9x
Roper Technologies$7.9B$3.2B6.1x5.7x15.2x14.6x
Illumina$4.3B$1.4B8.8x8.4x27.1x30.0x
GE HealthCare$21B$3.7B1.8x1.8x10.1x10.0x
Sartorius$4.1B$1.1B5.7x5.4x21.8x18.2x

This data is available for Pro users. Sign up to see all 4G Clinical competitors and their valuation data.

Start Free Trial

Common questions about 4G Clinical

When was 4G Clinical founded?4G Clinical was founded in 2015.
Where is 4G Clinical headquartered?4G Clinical is headquartered in United States.
Is 4G Clinical publicly listed?No, 4G Clinical is a private, VC-backed company.
How much funding has 4G Clinical raised?4G Clinical has raised $252M across 4 funding rounds.
What was 4G Clinical's last funding round?4G Clinical's last funding round was a $230M undisclosed-stage round in June 2021, led by Goldman Sachs Asset Management.
Who are 4G Clinical's investors?4G Clinical's investors include Schooner Capital and Goldman Sachs Asset Management.
Which companies are comparable to 4G Clinical?Companies comparable to 4G Clinical include Benchling, IQVIA, IDEXX Laboratories, GE HealthCare, ICON plc and Dental Monitoring.

See companies similar to 4G Clinical

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial